journal
https://read.qxmd.com/read/36964663/runx1-together-with-dat-mutations-predicted-poor-outcome-in-acute-myeloid-leukemia
#1
JOURNAL ARTICLE
Jinyan Xiao, Jundan Xie, Biqi Zhou, Yujie Liu, Jing Lu, Airui Jiang, Hong Yao, Qiaocheng Qiu, Zixuan Ding, Shengli Xue, Xiaowen Tang, Huiying Qiu, Suning Chen, Hongjie Shen, Depei Wu, Yang Xu
We retrospectively explored the prognostic impact of DAT mutations at diagnosis in 122 RUNX1mut AML patients. RUNX1 missense mutation was dominant in the RUNT domain, and frameshift mutation was dominant in the TAD domain. DAT mutations occurred in 38.5% of RUNX1mut AML. After propensity score matching, DATpos patients had worse two-year relapse-free survival (RFS) than DATneg patients ( p  = .041). Moreover, RUNX1high (VAF ≥ 37.6%) patients showed poorer two-year overall survival (OS) and RFS than RUNX1low (VAF < 37...
March 24, 2023: Leukemia & Lymphoma
https://read.qxmd.com/read/36961966/using-next-generation-sequencing-to-guide-treatment-of-co-existing-t-cell-lymphoma-and-chronic-myelomonocytic-leukemia
#2
JOURNAL ARTICLE
Ross T Salvaris, Benjamin Allanson, Chan Y Cheah
No abstract text is available yet for this article.
March 24, 2023: Leukemia & Lymphoma
https://read.qxmd.com/read/36960939/ebv-positive-pcnsl-in-older-patients-incidence-characteristics-tumor-pathology-and-outcomes-across-a-large-multicenter-cohort
#3
JOURNAL ARTICLE
Prashasti Agrawal, Kevin A David, Zhengming Chen, Suchitra Sundaram, Seo-Hyun Kim, Ryan Vaca, Yong Lin, Samuel Singer, Mary-Kate Malecek, Jordan Carter, Adam Zayac, Myung Sun Kim, Nishitha Reddy, Douglas Ney, Alma Habib, Christopher Strouse, Jerome Graber, Veronika Bachanova, Sidra Salman, Jean A Vendiola, Nasheed Hossain, Mazie Tsang, Ajay Major, Maher K Gandhi, Colm Keane, David A Bond, Matthew Folstad, Julie Chang, Angel Mier-Hicks, Pallawi Torka, Priya Rajakumar, Parameswaran Venugopal, Stephanie Berg, Michael Glantz, Samuel A Goldlust, Rahul Matnani, Pallavi Kumar, Thomas A Ollila, Johnny Cai, Stephen E Spurgeon, Alex G Sieg, Joseph Cleveland, Narendranath Epperla, Reem Karmali, Seema Naik, Sonali M Smith, James L Rubenstein, Brad S Kahl, Amy Chadburn, Andrew M Evens, Peter Martin
The objective of this multicenter retrospective study was to examine the incidence, patient characteristics, pathology, and outcomes associated with Epstein-Barr virus (EBV)-related CNS lymphoma (CNSL) in older patients. Among 309 CNSL patients aged ≥60, 11.7% had EBV + tumors of which 72.2% were solid organ transplant (SOT)-related post-transplant lymphoproliferative disorders (PTLD). Younger age, SOT or autoimmune disease, and immunosuppressive treatment correlated highly with EBV-positivity...
March 24, 2023: Leukemia & Lymphoma
https://read.qxmd.com/read/36960680/myeloid-sarcoma-with-npm1-mutation-may-be-clinically-and-genetically-distinct-from-aml-with-npm1-mutation-a-study-from-the-bone-marrow-pathology-group
#4
JOURNAL ARTICLE
Maximiliano Ramia de Cap, Leo P Wu, Christian Hirt, German A Pihan, Sanjay S Patel, Wayne Tam, Carlos E Bueso-Ramos, Rashmi Kanagal-Shamanna, Philipp W Raess, Alexa Siddon, Damodaran Narayanan, Elizabeth A Morgan, Geraldine S Pinkus, Emily F Mason, Eric D Hsi, Heesun J Rogers, Laura Toth, Kathryn Foucar, Stephanie N Hurwitz, Adam Bagg, Anton Rets, Tracy I George, Attilio Orazi, Daniel A Arber, Robert P Hasserjian, Olga K Weinberg
Myeloid sarcoma (MS) is currently considered equivalent to de novo acute myeloid leukemia (AML); however, the relationship between these entities is poorly understood. This retrospective multi-institutional cohort study compared 43 MS with NPM1 mutation to 106 AML with NPM1 mutation. Compared to AML, MS had more frequent cytogenetic abnormalities including complex karyotype ( p  = .009 and p  = .007, respectively) and was enriched in mutations of genes involved in histone modification, including ASXL1 ( p  = ...
March 24, 2023: Leukemia & Lymphoma
https://read.qxmd.com/read/36938919/the-impact-of-mild-to-moderate-chronic-kidney-disease-on-hospitalization-outcomes-in-patients-with-acute-myeloid-leukemia
#5
JOURNAL ARTICLE
Mohammad Ammad Ud Din, Hassan Saeed, Moazzam Shahzad, Hania Liaqat, Kendra Sweet
No abstract text is available yet for this article.
March 20, 2023: Leukemia & Lymphoma
https://read.qxmd.com/read/36938909/exposure-to-phenoxyacetic-acids-and-glyphosate-as-risk-factors-for-non-hodgkin-lymphoma-pooled-analysis-of-three-swedish-case-control-studies-including-the-sub-type-hairy-cell-leukemia
#6
JOURNAL ARTICLE
Lennart Hardell, Michael Carlberg, Marie Nordström, Mikael Eriksson
The association between pesticide exposure and non-Hodgkin lymphoma (NHL) including hairy cell leukemia (HCL) was analyzed in a pooled study of three case-control studies. Results on exposure to pesticides were based on 1,425 cases and 2,157 controls participating in the studies. Exposures were assessed by self-administered questionnaires completed as needed by phone. In the pooled univariate analyses adjusted by age, gender and year of diagnosis, exposure to herbicides of the phenoxyacetic acid type yielded statistically significant increased risk with odds ratio (OR) = 1...
March 20, 2023: Leukemia & Lymphoma
https://read.qxmd.com/read/36938892/phase-ii-study-of-dose-adjusted-epoch-as-initial-therapy-for-adults-with-high-risk-acute-lymphoblastic-leukemia
#7
JOURNAL ARTICLE
Ryan D Cassaday, Lucas C Zarling, Kelsey-Leigh A Garcia, Olga Sala-Torra, Philip A Stevenson, Christen H Martino, Yajuan J Liu, Min Fang, Mary-Elizabeth M Percival, Anna B Halpern, Pamela S Becker, Vivian G Oehler, Andrei R Shustov, Jason P Cooper, Johnnie J Orozco, Paul C Hendrie, Roland B Walter, Jerald P Radich, Lorinda A Soma, Elihu H Estey
Treatments for adults with newly-diagnosed acute lymphoblastic leukemia (ALL) may be prohibitively toxic and/or resource-intense. To address this, we performed a phase II study of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH). Imatinib or dasatinib was added for Ph + disease; rituximab was added when CD20+. Fifty-three patients were evaluable: 28 with Ph + disease, and 25 with Ph-. All patients had ≥1 high-risk clinical feature...
March 20, 2023: Leukemia & Lymphoma
https://read.qxmd.com/read/36924453/virtual-care-for-multiple-myeloma-in-the-covid-19-era-interrupted-time-series-analysis-of-veterans-health-administration-data
#8
JOURNAL ARTICLE
Christopher T Su, Jason C Chen, Jeremy B Sussman
No abstract text is available yet for this article.
March 16, 2023: Leukemia & Lymphoma
https://read.qxmd.com/read/36912366/rebound-of-covid-19-infection-in-patients-with-chronic-lymphocytic-leukemia-treated-for-sars-cov-2-with-nirmatrelvir-ritonavir-or-molnupiravir
#9
JOURNAL ARTICLE
Tamar Tadmor, Guy Melamed, Tal Patalon, Hilel Alapi, Lior Rokach
No abstract text is available yet for this article.
March 13, 2023: Leukemia & Lymphoma
https://read.qxmd.com/read/36908110/functional-humoral-and-cellular-response-of-monovalent-covid-19-vaccines-against-omicron-ba-2-variant-of-sars-cov-2-in-patients-with-chronic-lymphocytic-leukemia
#10
JOURNAL ARTICLE
Matteo Passerini, Tamar Ratishvili, Jonathon M Monroe, Zelalem Temesgen, Thomas E Witzig, Neil E Kay, Richard B Kennedy, Sameer A Parikh
We designed a prospective study to evaluate the humoral (using a surrogate virus neutralization test) and cellular (using an IFN-γ ELISpot) immune response among patients with chronic lymphocytic leukemia (CLL) against Wuhan-Hu-1 and Omicron BA.2 strains of SARS-CoV-2, after mRNA-based vaccination. The proportion of patients with a functional humoral response was higher among untreated CLL patients compared to treated CLL patients against both Wuhan-Hu-1 and Omicron BA.2 after the second and the third dose of vaccination, and at 12 months after the first dose...
March 12, 2023: Leukemia & Lymphoma
https://read.qxmd.com/read/36905177/wilms-tumor-1-expression-combined-with-genetic-mutations-for-prognostic-assessment-in-mds
#11
JOURNAL ARTICLE
Danqi Pan, Wenshu Zhao, Qianli Jiang, Changxin Yin, Han He, Libin Liao, Jieyu Ye, Min Dai
Overexpression of Wilms' tumor ( WT1 ) is frequently observed in myelodysplastic syndrome (MDS), which has been proposed as a prognostic marker. However, the prognostic role of WT1 expression in different contexts remains to be fully elucidated. We retrospectively assessed the relationships between WT1 levels and preexisting prognostic factors to further investigate its prognostic role under different contexts. In our study, WT1 expression was positively correlated with WHO 2016 classification and IPSS-R stratification...
March 11, 2023: Leukemia & Lymphoma
https://read.qxmd.com/read/36896574/is-this-the-end-for-immunochemotherapy-in-relapsed-refractory-chronic-lymphocytic-leukemia
#12
JOURNAL ARTICLE
Tadeusz Robak
No abstract text is available yet for this article.
March 10, 2023: Leukemia & Lymphoma
https://read.qxmd.com/read/36896478/results-from-a-phase-i-study-of-continuous-infusion-cladribine-high-dose-cytarabine-and-mitoxantrone-for-relapsed-refractory-high-grade-myeloid-neoplasms
#13
JOURNAL ARTICLE
Noam E Kopmar, Ted Gooley, Niall Curley, Kathryn Russell, Carole Shaw, Kelda Schonhoff, John Lim, Anna B Halpern, Roland B Walter, Bart L Scott, Jacob Appelbaum, Paul C Hendrie, Elihu H Estey, Mary-Elizabeth M Percival
No abstract text is available yet for this article.
March 9, 2023: Leukemia & Lymphoma
https://read.qxmd.com/read/36891630/poor-post-induction-outcomes-in-patients-with-acute-myeloid-leukemia-previously-treated-with-hypomethylating-agents
#14
JOURNAL ARTICLE
Michelle Y Zhang, Megan Othus, Carole Shaw, Kelda G Schonhoff, Anna B Halpern, Jacob Appelbaum, Paul C Hendrie, Roland B Walter, Elihu H Estey, Mary-Elizabeth M Percival
Patients with acute myeloid leukemia (AML) who have failed hypomethylating agents (HMA) have a poor prognosis. We examined whether high intensity induction chemotherapy could abrogate negative outcomes in 270 patients with AML or other high-grade myeloid neoplasms. Prior HMA therapy was significantly associated with a lower overall survival (OS) as compared to a reference group of patients with secondary disease without prior HMA therapy (median 7.2 vs 13.1 months). In patients with prior HMA therapy, high intensity induction was associated with a non-significant trend toward longer OS (median 8...
March 8, 2023: Leukemia & Lymphoma
https://read.qxmd.com/read/36891627/should-we-use-flow-cytometry-to-assess-bone-marrow-involvement-by-lymphoma
#15
JOURNAL ARTICLE
Rebeca Jurado, Mercè Aren, Marc Sorigue
No abstract text is available yet for this article.
March 8, 2023: Leukemia & Lymphoma
https://read.qxmd.com/read/36891619/car-t-cells-and-macrophages-in-large-b-cell-lymphoma-impact-on-toxicity-and-efficacy
#16
JOURNAL ARTICLE
Ajlan Al Zaki, Dustin McCurry, Paolo Strati
Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 is the current standard of care for the treatment of relapsed refractory large B cell lymphoma, demonstrating impressive response rates in the second- and third-line setting. Despite these advances, this treatment strategy can result in significant toxicities, such as cytokine release syndrome or immune effector cell associated neurotoxicity syndrome. While the exact mechanisms of these immune-mediated toxicities are not clearly understood, emerging pre-clinical and clinical studies have revealed the pivotal role of myeloid cells, particularly macrophages, as key contributors to the efficacy of treatments and as crucial mediators of toxicity...
March 8, 2023: Leukemia & Lymphoma
https://read.qxmd.com/read/36891585/tolerability-of-acalabrutinib-in-patients-with-cll-experience-of-a-tertiary-cancer-care-center
#17
JOURNAL ARTICLE
Alicia McGhie, Jenessa Lee, Alessandra Ferrajoli, Adam J DiPippo
No abstract text is available yet for this article.
March 8, 2023: Leukemia & Lymphoma
https://read.qxmd.com/read/36891578/a-phase-ii-study-to-evaluate-the-efficacy-of-low-dose-rasburicase-1-5mg-in-adolescent-and-adult-acute-leukemia-and-high-grade-lymphomas-with-tumor-lysis-syndrome
#18
JOURNAL ARTICLE
Swaratika Majumdar, Neha Sharma, Manju Sengar, Jayashree Thorat, Lingaraj Nayak, Avinash Bonda, Bhausaheb Bagal, Akhil Rajendra, Amit Sethi, Hasmukh Jain
The FDA recommended dose of rasburicase 0.2 mg/kg/day till the resolution of TLS or up to 5 days, might be in excess and is prohibitively expensive. The quality of evidence supporting low dose rasburicase is limited. The objective is to study the plasma uric acid response rate. This is a single center, non-randomised phase II study. Duration is 10 June 2017 till 30 July 2019. Study setting is at Adult Hematolymphoid Unit, Tata Memorial Center. Participants are patients with acute leukemia and high-grade lymphomas aged >/=18 years, with ECOG PS of 0-3, with either laboratory or clinical TLS...
March 8, 2023: Leukemia & Lymphoma
https://read.qxmd.com/read/36883878/effect-of-anti-cd38-monoclonal-antibodies-on-hepatitis-c-virus-replication-in-chronically-infected-patients-with-multiple-myeloma-a-prospective-series
#19
JOURNAL ARTICLE
Chia-Yu Chiu, Khalis Mustafayev, Hans C Lee, Elisabet E Manasanch, Eduardo Yepez Guevara, Harrys A Torres
No abstract text is available yet for this article.
March 8, 2023: Leukemia & Lymphoma
https://read.qxmd.com/read/36850055/report-of-four-acute-myeloid-leukemia-patients-with-sustained-complete-remission-with-less-frequent-administration-of-decitabine-and-venetoclax
#20
JOURNAL ARTICLE
Ahmed Aribi, Amandeep Salhotra, Brian Ball, Anthony Stein, Guido Marcucci, Vinod Pullarkat
No abstract text is available yet for this article.
February 27, 2023: Leukemia & Lymphoma
journal
journal
30440
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.